

**Pandemic Influenza Preparedness Framework for the sharing of influenza viruses and
access to vaccines and other benefits (PIP Framework)**

Standard Material Transfer Agreement 2

Article 1. Parties to the Agreement

Takeda Pharmaceutical Company Limited (hereinafter the "**Company**")
1-1, Doshomachi 4-chome, Chuo-ku,
Osaka 540-8645,
Japan

and

The World Health Organization (hereinafter "**WHO**")
20 avenue Appia
1211 Geneva 27
Switzerland

hereinafter together the "**Parties**" and each a "**Party**"

In connection with the PIP Framework, adopted by the World Health Assembly on 24 May 2011,
the Parties hereby agree as follows:

Article 2. Subject Matter of the Agreement

PIP biological materials as defined in Section 4.1 of the Framework (hereinafter "**Materials**")
transferred to the Company are subject to the provisions of the Agreement.

Article 3. Definitions

- (a) Terms defined in Section 4 of the PIP Framework shall have the same meaning when used in the context of this Agreement.
- (b) Other terms as may be agreed by the Parties in writing.
- (c) "**Term Sheets**" shall mean the terms and conditions describing the rights and obligations of each Party with regard to each of the Commitments (as defined below).
- (d) For the purposes of this Agreement, the Company shall be construed to refer not only to Takeda Pharmaceutical Company Limited, but also to any other company within the Takeda group of companies or affiliates thereof including but not limited to Takeda Vaccines, Inc.

Article 4. Obligations of WHO

WHO will report to the Advisory Group any exceptional transfers of Materials authorized by the Director-General under Article 5.4 below.

Article 5. Obligations of the Company

5.1 The Company agrees to comply with the commitments below (the “**Commitments**”), in accordance with the terms set out hereunder and in the Term Sheets annexed to this Agreement and forming an integral part thereof, including with respect to timetables established thereunder.

5.1.1 The Company, as a manufacturer of vaccines, commits to the following subject to and in accordance with the respective Term Sheet with regard to each influenza pandemic during the term of this Agreement:

- 1. Donate 8% of real time pandemic vaccine production to WHO (see Annex 1).*
- 2. Reserve 2% of real time pandemic vaccine production at affordable prices to WHO (see Annex 2).*

5.2 The Company shall ensure that the Materials are handled in accordance with applicable WHO guidelines and national bio-safety standards.

5.3 If applicable, the Company shall appropriately acknowledge in presentations and publications, the contributions of WHO laboratories providing the Materials, using existing scientific guidelines.

5.4 The Company shall only further transfer the Materials if the prospective recipient has concluded a Standard Material Transfer Agreement (hereinafter “**SMTA**”) with WHO. The Company shall report any such further transfers to WHO. The Director-General may, under exceptional circumstances, allow the Materials to be transferred to a prospective recipient while requesting this aforementioned recipient to enter into an SMTA. For the avoidance of any doubt, such restricted transfers are understood not to include provision by the Company of Materials for utilization on its behalf to entities under contract to the Company, provided that in such case (a) the Materials are returned to the Company or destroyed in accordance with the appropriate bio-safety standards in Japan or other applicable country at the end of utilization; and (b) the Materials shall not be utilized by such entities for research, development or production other than as directed by the Company; and (c) the Company shall, in such cases, remain fully responsible for the compliance by such entities of the obligations for handling the Materials in accordance with this Agreement.

5.5 The Company may exchange the Materials with any other holder of an SMTA concluded with WHO.

Article 6. Term Sheets

6.1 The Term Sheets specify the terms for each of the Commitments in Article 5 above, and shall form Annexes 1 and 2 of the Agreement. The Annexes shall be an integral part of this Agreement.

6.2 At the request of either Party at any time, but at a minimum every four (4) years from the signature of this Agreement, the Parties will review the provisions contained in the Term Sheets to evaluate if modification is necessary and the Term Sheets may be adapted by mutual written agreement of the Parties as a result of such review. Any modification requested by either Party shall be discussed by the Parties in good faith and the Parties shall use reasonable efforts to agree on such modifications within three months of starting such discussions.

6.3 In case of an imminent risk of a pandemic, and at the latest upon declaration by WHO of a pandemic, the Parties will review (and if necessary adapt) the Term Sheets with the objective of ensuring that all mechanisms are in place to enable the speedy implementation of the Commitments once a pandemic is declared. The Parties will also conduct an after action review of the Term Sheets after the end of a pandemic event.

Article 7. Dispute Resolution

7.1 If a dispute cannot be resolved after three-months from its beginning, through negotiations or other amicable, non-binding means of the Parties' choice, including conciliation, disputes shall be subject to, and finally settled under, binding arbitration on conditions that are mutually agreed by the Parties. The Parties agree that such conditions include use of the Rules of Arbitration of the International Chamber of Commerce by a panel of three arbitrators appointed in accordance with the said Rules. The seat of the arbitration shall be in Geneva, Switzerland. The arbitral proceedings shall be conducted in English.

7.2 Any matter relating to the interpretation or application of this Agreement which is not covered by its terms will be resolved by reference to the laws of Switzerland.

Article 8. Liability and Indemnity

Provisions on liability and indemnity are contained in the relevant Term Sheets.

Article 9. Privileges and Immunity

Nothing in or relating to these clauses shall imply the obligation of WHO to submit to any national legislation or jurisdiction, or be deemed a waiver of any of the privileges and immunities of WHO in conformity with the Convention on the Privileges and Immunities of the Specialized Agencies approved by the General Assembly of the United Nations on November 21, 1947 or otherwise under any national or international law, convention or agreement.

Article 10. Name and Emblem and Provision of Information

10.1 Except as otherwise explicitly provided in this Agreement, neither Party shall, in any statement or material of an advertising or promotional nature, refer to the relationship of the Parties under this Agreement, or otherwise use the other Party's name, acronym and/or emblem, without the prior written consent of that other Party.

10.2 When information provided in the context of this Agreement is described by the Party providing it as confidential, the receiving Party will treat the information as strictly confidential and will only use the information for the purpose for which it was provided. The receiving Party undertakes to disclose any such confidential information only to persons who have a need to know and who are bound by like obligations of confidentiality and restrictions on use as contained herein.

10.3 However, there will be no obligation of confidentiality or restriction on use where:

- (a) the information is publicly available, or becomes publicly available, otherwise than by action of the receiving Party; or
- (b) the information was already known to the receiving Party (as evidenced by its written records) prior to its receipt; or
- (c) the information was received from a third Party not in breach of an obligation of confidentiality; or
- (d) the receiving Party is required by law to disclose the information, provided that the receiving Party will immediately notify the disclosing Party in writing of such obligation and provide adequate opportunity to the disclosing Party to object to such disclosure or request confidential treatment thereof.

Article 11. Warranties

Each Party warrants to the other Party that it has the full power to enter into this Agreement, to carry out its obligations under this Agreement and to grant the rights and benefits granted by it to the other Party under this Agreement.

Article 12. Duration of Agreement

This Agreement will become effective upon the signing by both Parties and shall remain in effect until 31 December 2031, unless terminated by either Party in accordance with Article 13 below.

Article 13. Termination

13.1 Either Party shall have the right to terminate this Agreement at any time with one hundred and eighty (180) days written notice to the other Party. If a pandemic occurs during such notice period, all obligations under this Agreement will survive and termination will take effect only after both fulfilment of the obligations by the Parties under the respective Term Sheet and the announcement of the end of the pandemic.

13.2 In case of a termination of this Agreement by the Company, the Company shall, when such termination takes effect, immediately cease any and all use of any Materials and shall return to the provider or destroy (as advised by the provider) any such Materials.

Article 14. Force Majeure

No Party shall be liable for any delay in the performance of or failure to perform its obligations under this Agreement, where such delay or failure is caused by Force Majeure ("Force Majeure" is defined in the relevant Term Sheets).

Article 15. Miscellaneous

15.1 Any notice to be given between the Parties shall be effectively given if sent by letter, fax or similar means of communication, postage prepaid or charged to the sender and addressed to the other Party at the address shown below:

(a) If to WHO:

World Health Organization,
20 Avenue Appia
1211 Geneva 27
Switzerland

Attention: PIP Framework Secretariat, with copy to pipframework@who.int

(b) If to the Company:

Takeda Pharmaceutical Company Limited
1-1, Doshomachi 4-chome,
Chuo-ku, Osaka 540-8645
Japan

Attention: General Manager, Japan Vaccine Business Unit

15.2 This Agreement, including any current or future Annexes, contains all the rights, obligations and terms made by the Parties in connection with the subject matter detailed herein. Any amendment of the Agreement, including any amendment of this section 15.2, is only valid if made in writing as an amendment to this Agreement and signed by authorized signatories of the Parties.

15.3 Should any part of this Agreement, including its Annexes, be or become void, ineffective or unenforceable for any reason, the validity of the remaining sections of this Agreement shall not be affected. In such a case, the ineffective section or sub-section shall be deemed as replaced by provisions achieving the purpose of this Agreement as far as possible.

Article 16. Signature and Acceptance

In WITNESS whereof, this Agreement has been duly executed by the Parties.

SIGNED for and on behalf of WHO

SIGNED for and on behalf of Takeda
Pharmaceutical Company Limited

Signature



Name: Dr Peter Salama

Title: Deputy Director-General
WHO Health Emergencies Programme

Date:

29/2/18



Signature

Name: Rajeev Venkayya, MD

Title: President, Global Vaccine
Business Unit

Date: March 16, 2018